Mark Berger
Chief Tech/Sci/R&D Officer presso GENPREX, INC.
Patrimonio netto: 14 322 $ in data 31/03/2024
Posizioni attive di Mark Berger
Società | Posizione | Inizio | Fine |
---|---|---|---|
GENPREX, INC. | Chief Tech/Sci/R&D Officer | 01/01/2017 | - |
Storia della carriera di Mark Berger
Precedenti posizioni note di Mark Berger
Società | Posizione | Inizio | Fine |
---|---|---|---|
ACTINIUM PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 18/01/2017 | 24/09/2021 |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | 01/09/2013 | 01/01/2017 |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Chief Tech/Sci/R&D Officer | 01/06/2011 | 01/09/2013 |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Corporate Officer/Principal | 01/03/2007 | 01/06/2011 |
GSK PLC | Corporate Officer/Principal | 01/09/2002 | 01/02/2007 |
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Corporate Officer/Principal | - | - |
University of Pennsylvania | Corporate Officer/Principal | - | - |
Formazione di Mark Berger
Wesleyan University | Undergraduate Degree |
The University of Virginia School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
2 | |
Regno Unito | 2 |
Posizioni
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 4 |
Undergraduate Degree | 1 |
Settori
Health Technology | 7 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
GSK PLC | Health Technology |
ACTINIUM PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 5 |
---|---|
Wyeth Pharmaceuticals LLC
Wyeth Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Wyeth Pharmaceuticals LLC develops pharmaceutical, biotechnology and vaccine technologies. The company was registered on May 5, 2003 and is headquartered in Collegeville, PA. | Health Technology |
Genprex, Inc. | |
Gemin X Pharmaceuticals US, Inc.
Gemin X Pharmaceuticals US, Inc. BiotechnologyHealth Technology Gemin X Pharmaceuticals US Inc. is engaged in the development of cancer therapeutics. It offers mimetic and telomere capping programs, as well as screening, medicinal chemistry, and preclinical development services. The company was founded by Gordon C. Shore in 1998 and is headquartered in Malvern, PA. | Health Technology |
Deciphera Pharmaceuticals LLC
Deciphera Pharmaceuticals LLC BiotechnologyHealth Technology Deciphera Pharmaceuticals LLC discovers and develops pharmaceutical preparations. It designs kinase inhibitor therapies that target the hallmarks of cancer biology. The firm’s clinical pipeline of kinase inhibitors includes tumor-targeted therapies and immuno-targeted therapies. It offers DCC-2618, Rebastinib, and DCC-3014. The company was founded by Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. | Health Technology |
Kadmon Corp. LLC
Kadmon Corp. LLC Pharmaceuticals: MajorHealth Technology Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY. | Health Technology |
- Borsa valori
- Insiders
- Mark Berger
- Esperienza